The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression

Laurie E. Littlepage, Adam S. Adler, Hosein Kouros-Mehr, Guiqing Huang, Jonathan Chou, Sheryl R. Krig, Obi L. Griffi th, James E. Korkola, Kun Qu, Devon A. Lawson, Qing Xue, Mark D. Sternlicht, Gerrit J P Dijkgraaf, Paul Yaswen, Hope S. Rugo, Colleen A Sweeney, Colin C. Collins, Joe W. Gray, Howard Y. Chang, Zena Werb

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility, and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identifi ed candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We show that the nucleoside analogue triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance and inhibits signaling events [e.g., phospho-AKT, phospho-mitogen-activated protein kinase (MAPK)] in vivo. Our data suggest that ZNF217 is a biomarker of poor prognosis and a therapeutic target in patients with breast cancer and that triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. Because ZNF217 is amplifi ed in numerous cancers, these results have implications for other cancers. SIGNIFICANCE: This study finds that ZNF217 is a poor prognostic indicator and therapeutic target in patients with breast cancer and may be a strong biomarker of triciribine treatment efficacy in patients. Because previous clinical trials for triciribine did not include biomarkers of treatment efficacy, this study provides a rationale for revisiting triciribine in the clinical setting as a therapy for patients with breast cancer who overexpress ZNF217.

Original languageEnglish (US)
Pages (from-to)638-651
Number of pages14
JournalCancer Discovery
Volume2
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

triciribine
Transcription Factors
Biomarkers
Breast Neoplasms
Neoplasms
Therapeutics
Adult Stem Cells
Growth
Mitogen-Activated Protein Kinases
Oncogenes
Nucleosides
Computer Simulation
Down-Regulation
Chromosomes
Clinical Trials
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Littlepage, L. E., Adler, A. S., Kouros-Mehr, H., Huang, G., Chou, J., Krig, S. R., ... Werb, Z. (2012). The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discovery, 2(7), 638-651. https://doi.org/10.1158/2159-8290.CD-12-0093

The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression. / Littlepage, Laurie E.; Adler, Adam S.; Kouros-Mehr, Hosein; Huang, Guiqing; Chou, Jonathan; Krig, Sheryl R.; Griffi th, Obi L.; Korkola, James E.; Qu, Kun; Lawson, Devon A.; Xue, Qing; Sternlicht, Mark D.; Dijkgraaf, Gerrit J P; Yaswen, Paul; Rugo, Hope S.; Sweeney, Colleen A; Collins, Colin C.; Gray, Joe W.; Chang, Howard Y.; Werb, Zena.

In: Cancer Discovery, Vol. 2, No. 7, 07.2012, p. 638-651.

Research output: Contribution to journalArticle

Littlepage, LE, Adler, AS, Kouros-Mehr, H, Huang, G, Chou, J, Krig, SR, Griffi th, OL, Korkola, JE, Qu, K, Lawson, DA, Xue, Q, Sternlicht, MD, Dijkgraaf, GJP, Yaswen, P, Rugo, HS, Sweeney, CA, Collins, CC, Gray, JW, Chang, HY & Werb, Z 2012, 'The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression', Cancer Discovery, vol. 2, no. 7, pp. 638-651. https://doi.org/10.1158/2159-8290.CD-12-0093
Littlepage, Laurie E. ; Adler, Adam S. ; Kouros-Mehr, Hosein ; Huang, Guiqing ; Chou, Jonathan ; Krig, Sheryl R. ; Griffi th, Obi L. ; Korkola, James E. ; Qu, Kun ; Lawson, Devon A. ; Xue, Qing ; Sternlicht, Mark D. ; Dijkgraaf, Gerrit J P ; Yaswen, Paul ; Rugo, Hope S. ; Sweeney, Colleen A ; Collins, Colin C. ; Gray, Joe W. ; Chang, Howard Y. ; Werb, Zena. / The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression. In: Cancer Discovery. 2012 ; Vol. 2, No. 7. pp. 638-651.
@article{a8575c69805a44e281795763f14576b1,
title = "The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression",
abstract = "The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20{\%} to 30{\%} of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility, and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identifi ed candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We show that the nucleoside analogue triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance and inhibits signaling events [e.g., phospho-AKT, phospho-mitogen-activated protein kinase (MAPK)] in vivo. Our data suggest that ZNF217 is a biomarker of poor prognosis and a therapeutic target in patients with breast cancer and that triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. Because ZNF217 is amplifi ed in numerous cancers, these results have implications for other cancers. SIGNIFICANCE: This study finds that ZNF217 is a poor prognostic indicator and therapeutic target in patients with breast cancer and may be a strong biomarker of triciribine treatment efficacy in patients. Because previous clinical trials for triciribine did not include biomarkers of treatment efficacy, this study provides a rationale for revisiting triciribine in the clinical setting as a therapy for patients with breast cancer who overexpress ZNF217.",
author = "Littlepage, {Laurie E.} and Adler, {Adam S.} and Hosein Kouros-Mehr and Guiqing Huang and Jonathan Chou and Krig, {Sheryl R.} and {Griffi th}, {Obi L.} and Korkola, {James E.} and Kun Qu and Lawson, {Devon A.} and Qing Xue and Sternlicht, {Mark D.} and Dijkgraaf, {Gerrit J P} and Paul Yaswen and Rugo, {Hope S.} and Sweeney, {Colleen A} and Collins, {Colin C.} and Gray, {Joe W.} and Chang, {Howard Y.} and Zena Werb",
year = "2012",
month = "7",
doi = "10.1158/2159-8290.CD-12-0093",
language = "English (US)",
volume = "2",
pages = "638--651",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - The transcription factor ZNF217 Is a prognostic biomarker and therapeutic target during breast cancer progression

AU - Littlepage, Laurie E.

AU - Adler, Adam S.

AU - Kouros-Mehr, Hosein

AU - Huang, Guiqing

AU - Chou, Jonathan

AU - Krig, Sheryl R.

AU - Griffi th, Obi L.

AU - Korkola, James E.

AU - Qu, Kun

AU - Lawson, Devon A.

AU - Xue, Qing

AU - Sternlicht, Mark D.

AU - Dijkgraaf, Gerrit J P

AU - Yaswen, Paul

AU - Rugo, Hope S.

AU - Sweeney, Colleen A

AU - Collins, Colin C.

AU - Gray, Joe W.

AU - Chang, Howard Y.

AU - Werb, Zena

PY - 2012/7

Y1 - 2012/7

N2 - The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility, and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identifi ed candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We show that the nucleoside analogue triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance and inhibits signaling events [e.g., phospho-AKT, phospho-mitogen-activated protein kinase (MAPK)] in vivo. Our data suggest that ZNF217 is a biomarker of poor prognosis and a therapeutic target in patients with breast cancer and that triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. Because ZNF217 is amplifi ed in numerous cancers, these results have implications for other cancers. SIGNIFICANCE: This study finds that ZNF217 is a poor prognostic indicator and therapeutic target in patients with breast cancer and may be a strong biomarker of triciribine treatment efficacy in patients. Because previous clinical trials for triciribine did not include biomarkers of treatment efficacy, this study provides a rationale for revisiting triciribine in the clinical setting as a therapy for patients with breast cancer who overexpress ZNF217.

AB - The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility, and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identifi ed candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We show that the nucleoside analogue triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance and inhibits signaling events [e.g., phospho-AKT, phospho-mitogen-activated protein kinase (MAPK)] in vivo. Our data suggest that ZNF217 is a biomarker of poor prognosis and a therapeutic target in patients with breast cancer and that triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. Because ZNF217 is amplifi ed in numerous cancers, these results have implications for other cancers. SIGNIFICANCE: This study finds that ZNF217 is a poor prognostic indicator and therapeutic target in patients with breast cancer and may be a strong biomarker of triciribine treatment efficacy in patients. Because previous clinical trials for triciribine did not include biomarkers of treatment efficacy, this study provides a rationale for revisiting triciribine in the clinical setting as a therapy for patients with breast cancer who overexpress ZNF217.

UR - http://www.scopus.com/inward/record.url?scp=84866310283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866310283&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-12-0093

DO - 10.1158/2159-8290.CD-12-0093

M3 - Article

VL - 2

SP - 638

EP - 651

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 7

ER -